{
    "title": "Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis",
    "pmid": "38568509",
    "pmcid": "PMC10993165",
    "study_parameters": [
        {
            "Study Parameters ID": 1452437520,
            "Variant Annotation ID": 1452437420,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "2 studies, SJS/TEN v tolerant controls",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.01,
            "Confidence Interval Start": 1.56,
            "Confidence Interval Stop": 5.8,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1452437420"
        },
        {
            "Study Parameters ID": 1452437426,
            "Variant Annotation ID": 1452437420,
            "Study Type": "meta-analysis",
            "Study Cases": 158.0,
            "Study Controls": 226.0,
            "Characteristics": "2 studies, SCAR v tolerant controls",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.23,
            "Confidence Interval Start": 1.2,
            "Confidence Interval Stop": 4.14,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1452437420"
        },
        {
            "Study Parameters ID": 1452438988,
            "Variant Annotation ID": 1452438980,
            "Study Type": "meta-analysis",
            "Study Cases": 158.0,
            "Study Controls": 226.0,
            "Characteristics": "2 studies, SCAR v tolerant controls",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.96,
            "Confidence Interval Start": 1.58,
            "Confidence Interval Stop": 22.56,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1452438980"
        },
        {
            "Study Parameters ID": 1452438989,
            "Variant Annotation ID": 1452439000,
            "Study Type": "meta-analysis",
            "Study Cases": 158.0,
            "Study Controls": 226.0,
            "Characteristics": "2 studies, SCAR v tolerant controls",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.01",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.47,
            "Confidence Interval Start": 1.42,
            "Confidence Interval Stop": 8.48,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1452439000"
        },
        {
            "Study Parameters ID": 1452438990,
            "Variant Annotation ID": 1452439000,
            "Study Type": "meta-analysis",
            "Study Cases": null,
            "Study Controls": null,
            "Characteristics": "2 studies, SJS/TEN v tolerant controls",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.13,
            "Confidence Interval Start": 1.96,
            "Confidence Interval Stop": 13.47,
            "Biogeographical Groups": "Multiple groups",
            "Variant Annotation ID_norm": "1452439000"
        }
    ],
    "var_drug_ann": [],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1452437420,
            "Variant/Haplotypes": "HLA-B*15:02",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
            "PMID": 38568509,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). ",
            "Sentence": "HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
            "Alleles": "*15:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "38568509",
            "Variant Annotation ID_norm": "1452437420"
        },
        {
            "Variant Annotation ID": 1452438980,
            "Variant/Haplotypes": "HLA-B*13:01",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
            "PMID": 38568509,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls.",
            "Sentence": "HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
            "Alleles": "*13:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "38568509",
            "Variant Annotation ID_norm": "1452438980"
        },
        {
            "Variant Annotation ID": 1452439000,
            "Variant/Haplotypes": "HLA-B*38:02",
            "Gene": "HLA-B",
            "Drug(s)": "sulfamethoxazole, sulfamethoxazole / trimethoprim",
            "PMID": 38568509,
            "Phenotype Category": "Toxicity",
            "Significance": "yes",
            "Notes": "The associations between patients with SMX/CTX-induced SCARs and different HLA alleles are presented in Figure 2, Table 2, and eTable 3 in Supplement 1. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. \"In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). ",
            "Sentence": "HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.",
            "Alleles": "*38:02",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions",
            "Multiple phenotypes And/or": "or",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "or",
            "Population types": null,
            "Population Phenotypes or diseases": null,
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "38568509",
            "Variant Annotation ID_norm": "1452439000"
        }
    ],
    "var_fa_ann": []
}